MHE Question of the Week: Health Insurance Coverage of GLP-1s for Weight Loss
Please pick the statement that most closely resembles your view of health insurance coverage of GLP-1s for weight loss.
The glucagon-like peptide 1 (GLP-1) drugs is a class that includes now-famous Ozempic (semaglutide) and Mounjaro (tirzepatide), which were approved by the FDA as diabetes treatments but have been used off-label for weight loss. After FDA approvals, on-label versions are available for weight, marketed under the names Wegovy (semaglutide) and Zepbound (tirzepatide). Prescriptions of the GLP-1s have soared as patients and prescribers have flocked to a pharmaceutical answer to the U.S. obesity epidemic. The cost has strained insurer budgets. There are also questions about the long-term outcomes of GLP-1s and how long people are sticking with the treatments, which are administered as injections.
Please pick the statement that most closely resembles your view of health insurance coverage of GLP-1s for weight loss.
Please pick the statement that most closely resembles your view of health insurance coverage of GLP-1s for weight loss
We want to know what you’re thinking! Every Monday morning the editors of Managed Healthcare Executive are posing a question to our readers about a timely issue in U.S. healthcare. Answers will be published every Friday.
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
